RS BioTherapeutics has filed a notice of an exempt offering of securities to raise $10,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, RS BioTherapeutics is raising $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Dean Hart played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About RS BioTherapeutics
RS BioTherapeutics first investigational compound (RSBT-001) is a semi-synthetic, nebulized, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. Our premise is that RSBT1 provides therapeutic benefit through modulation of the Interleukin response to inflammation and modulation of alveolar macrophages responsible for fibrotic changes within the lungs. RSBT-001 is unique in that it is a polar adaptive molecule exhibiting both hydrophilic and lipophilic properties, which leads to high absorption and bioavailability enhancing therapeutic benefit.
To learn more about RS BioTherapeutics, visit http://www.rsbiotherapeutics.com/
Contact:
Dean Hart, Chief Executive Officer
717-433-5390
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.